Aditxt's Adimune Advances DNA-Based Immune Reprogramming Platform with 96 Patents, Eyes 2026 Clinical Trials
核心洞察
Adimune (搜索) has secured 96 granted and 22 pending patents for its DNA-based therapeutic platform designed to reprogram the immune system (搜索) and restore natural tolerance.
The company plans to seek FDA submission and approval for first-in-human trials targeting type 1 diabetes (搜索) and stiff person syndrome (搜索) in early 2026.
Adimune (搜索)'s lead candidate ADI-100 addresses high-need autoimmune conditions including type 1 diabetes (搜索), psoriasis (搜索), and stiff person syndrome (搜索) within a market estimated at over $160 billion by 2030.
Aditxt's wholly owned subsidiary Adimune (搜索) has strengthened its intellectual property position with 96 granted and 22 pending patents supporting its DNA-based therapeutic platform designed to reprogram the immune system (搜索). The pre-clinical stage biopharmaceutical company plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes (搜索) and stiff person syndrome (搜索) targeted for early 2026.
Robust Patent Portfolio Supports Market Strategy
Adimune (搜索)'s intellectual property portfolio, owned or exclusively licensed by parent company Aditxt (NASDAQ: ADTX), positions the company to address the global autoimmune therapeutics market estimated at over $160 billion by 2030. The platform represents what company leadership describes as a fundamental shift in immune system (搜索) biology.
"We believe Adimune (搜索) has the potential to represent a fundamental shift in how we think about the immune system (搜索) and biology in general," said Amro Albanna, Co-founder and Chief Executive Officer of Aditxt. "If successful in harnessing DNA instructions and a proprietary delivery platform to reprogram the immune system, Adimune has the potential to lead a new era of addressing diseases through programming instructions designed to create innovative treatments."
DNA-Based Immune Modulation Technology
The company's approach combines DNA instructions with a proprietary delivery platform to achieve what executives describe as "digital-like precision" in immune system (搜索) retraining. Unlike traditional approaches that rely on chronic immunosuppression, Adimune (搜索)'s platform is designed to restore natural immune tolerance.
"Autoimmunity is one of the most complex and urgent challenges in medicine," said Friedrich Kapp, Co-Chief Executive Officer of Adimune (搜索). "Our platform is designed to reprogram the immune system (搜索), restoring tolerance without the burden of chronic immunosuppression."
Lead Candidate Targets High-Need Conditions
Adimune (搜索)'s first product candidate, ADI-100, targets high-need autoimmune conditions including type 1 diabetes (搜索), psoriasis (搜索), and stiff person syndrome (搜索). The company's mission focuses on advancing immune health by providing targeted, long-term solutions that minimize reliance on chronic immunosuppression for autoimmune diseases (搜索) and organ transplantation.
The planned FDA submission for first-in-human trials in early 2026 represents a critical milestone in translating the company's vision into clinical applications. Kapp emphasized that this timeline "represents a critical milestone toward translating this vision into real solutions for patients."
Strategic Position in Autoimmune Market
Adimune (搜索) operates as part of Aditxt's broader social innovation platform, which accelerates promising health innovations through an ecosystem of research institutions, industry partners, and shareholders. The parent company currently operates programs focused on immune health and precision health, with plans to expand into women's health through a proposed acquisition of Evofem (搜索) targeted for the second half of 2025.